Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal intelligence from Strategic Transactions.
Unraveling a collaboration that has seen numerous twists and turns since being signed in 2010, GlaxoSmithKline PLC has decided against exercising its option for Ionis Pharmaceuticals Inc.'s inotersen, a Phase III antisense candidate for polyneuropathy related to hereditary transthyretin amyloidosis (hATTR-PN). In tandem with that decision, announced Aug
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?